Jane Street’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-48,900
| Closed | -$111K | – | 10647 |
|
|
2024
Q2 | $111K | Sell |
48,900
-1,600
| -3% | -$6.11K | ﹤0.01% | 8687 |
|
|
2024
Q1 | $218K | Buy |
50,500
+22,500
| +80% | +$78.4K | ﹤0.01% | 8062 |
|
|
2023
Q4 | $85.4K | Buy |
+28,000
| New | +$52.6K | ﹤0.01% | 8641 |
|
|
2022
Q4 | – | Sell |
-12,100
| Closed | -$151K | – | 10369 |
|
|
2022
Q3 | $151K | Sell |
12,100
-1,500
| -11% | -$17.1K | ﹤0.01% | 8395 |
|
|
2022
Q2 | $67K | Sell |
13,600
-27,500
| -67% | -$152K | ﹤0.01% | 8826 |
|
|
2022
Q1 | $312K | Buy |
41,100
+23,500
| +134% | +$223K | ﹤0.01% | 8339 |
|
|
2021
Q4 | $180K | Sell |
17,600
-26,900
| -60% | -$343K | ﹤0.01% | 8890 |
|
|
2021
Q3 | $597K | Sell |
44,500
-8,700
| -16% | -$142K | ﹤0.01% | 6946 |
|
|
2021
Q2 | $1.17M | Buy |
53,200
+5,400
| +11% | +$120K | ﹤0.01% | 5503 |
|
|
2021
Q1 | $1.15M | Buy |
47,800
+1,000
| +2% | +$23.2K | ﹤0.01% | 5195 |
|
|
2020
Q4 | $842K | Buy |
+46,800
| New | +$699K | ﹤0.01% | 4945 |
|
Jane Street's GTHX Position: Q3 2024 in Review
Jane Street sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 64,916 shares — an estimated $148K sold.
Jane Street first reported a position in GTHX in Q3 2018 and held it in 17 quarters. The position peaked at $2.88M in Q1 2021. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Jane Street reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Jane Street sold 64,916 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $148K.
- Jane Street first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2018 and held it in 17 quarters.
- Jane Street's G1 Therapeutics, Inc. Common Stock position peaked at $2.88M in Q1 2021.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Jane Street's 13F filing for Q3 2024, filed 15 Nov 2024.